Understand the source comparison
5-Amino-1MQ Animal vs Human Research: Direct Comparison
NNMT Expression Target High expression in white adipose tissue and liver; 10–20× elevated in obese vs lean mice Variable expression across adipose depots; obesity correlation inconsistent in human cohorts Therapeutic target may not be as prominent or consisten
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- NNMT Expression Target
- High expression in white adipose tissue and liver; 10–20× elevated in obese vs lean mice
- Variable expression across adipose depots; obesity correlation inconsistent in human cohorts
- Therapeutic target may not be as prominent or consistent in humans as in rodent models
- Weight Loss Magnitude
- 30% body weight reduction over 11 days in diet-induced obese mice at 50 mg/kg/day
- No published efficacy data; anecdotal reports unverified
- Rodent outcomes likely overstate human potential due to metabolic rate and BAT activity differences
- Mechanism of Action
- NNMT inhibition → NAD+ elevation → SIRT1 activation → thermogenesis and fat oxidation
- Mechanism not confirmed in human tissue; NAD+ response to NNMT inhibition unverified
- Pathway is biologically plausible but requires human validation before therapeutic claims
- Thermogenic Contribution
- Significant BAT activation measured via indirect calorimetry and UCP1 gene expression
- Adult human BAT mass and activity far lower than rodents; thermogenic potential uncertain
- Energy expenditure increase in humans likely smaller than in mice due to limited BAT depots
- Safety and Tolerability
- No acute toxicity observed at therapeutic doses in rodent studies
- No published human safety data; long-term effects unknown
- Risk profile cannot be assessed without Phase I trial data; NNMT's role in methylation pathways raises questions about chronic inhibition
- Dose Conversion
- 50 mg/kg/day in mice translates to approximately 4 mg/kg/day in humans via allometric scaling (240–320 mg/day for a 70 kg adult)
- Dosing protocols in anecdotal use range from 30–100 mg/day. Well below predicted equivalent dose
- Current human dosing may be subtherapeutic if rodent dose-response applies; dose-ranging studies needed